nach oben

Erschienen in:

Open Access 06.09.2022 | Original Article

Case Series Analysis of Male Breast Cancer

verfasst von: Chao Li, Xujun Li

Erschienen in: Indian Journal of Surgery | Ausgabe 4/2023

Abstract

Male breast cancer is a rare disease, accounting for less than 1% of all cases of breast cancer. However, the incidence of male breast cancer is increasing. In this study, we systematically analyzed the cases of male breast cancer and evaluated the management of operable male breast cancer in daily clinical practice according to the international clinical guidelines. Data of male breast cancer characteristics and management were recorded from our electronic database. We present a case series of male breast cancer patients treated at our institution between 2013 and 2021 and summarize the recommendations on management of male patients with breast cancer. Twenty-six patients met the search criteria. The majority of tumors were hormone-receptor positive and human epidermal growth factor receptor 2 negative. Two tumors were derived from axillary accessory breast. All patients underwent mastectomy. Fifteen patients received adjuvant chemotherapy containing anthracycline or taxane. Ten patients received adjuvant radiotherapy for lymph node metastasis. Twenty-five patients received adjuvant endocrine therapy. None of patients received anti-human epidermal growth factor receptor 2 therapy. During the median follow-up period of 37 months, one patient died of previous lung cancer recurrence and one patient developed lung metastases 2 years after breast surgery. No recurrence or distant metastasis occurred in the other twenty-four patients. The incidence of male breast cancer is low. In this study, we present twenty-six cases of male patients with operable breast cancer in our department. All of them received surgery and adjuvant treatment. Early diagnosis and combined therapy benefit male patients with breast cancer. Surgery together with adjuvant treatment can bring a good prognosis.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Introduction

Breast cancer is the most common malignancy among women worldwide [1]. Compared to female breast cancer, the incidence of male breast cancer is low, accounting for less than 1% of all cases of breast cancer [2]. The incidence of male breast cancer is also low in all male malignancies. However, the incidence of male breast cancer is increasing with growing rate of male gynecomastia [2]. With the low incidence, there were no large-scale prospective randomized clinical trials conducted to determine effective therapy for male patients. Diagnostic and treatment evidence for male breast cancer is limited. Currently, male breast cancer is treated similar to female breast cancer [3, 4]. For the different pathogenesis of male breast cancer and lack of knowledge about male breast cancer, the prognosis of male patients with breast cancer is worse than that of female patients [5, 6, 7]. In the present paper, we present a case series of male patients diagnosed with breast cancer treated at Department of Breast Surgery, Hwa Mei Hospital, University of Chinese Academy of Sciences, between 2013 and 2021. We systematically analyzed the cases of male breast cancer and evaluated the management of operable male breast cancer according to the international clinical guidelines.

Patients and Methods

Operable male patients with breast cancer were selected from electronic database by using the search criteria of “breast cancer” and “male” between January 1, 2013, and December 31, 2021. Patients with distant metastasis were excluded. Patients and tumor characteristics, treatment, and follow-ups were collected. Data were analyzed applying descriptive statistics. The study was approved by the ethics committee of Hwa Mei Hospital, University of Chinese Academy of Sciences.

Result

Twenty-six patients matched the search criteria in the period between January 1, 2013, and December 31, 2021. The average age of the patients was 60 (from 37 to 82) years. About 58% of the patients were elderly men over 60 years old. Twenty-four cases of breast cancer were derived from breast, and the other two cases were derived from axillary accessory breast. Twenty-four cases underwent mastectomy, and two cases underwent accessory mastectomy. Fourteen patients received axillary lymph nodes dissection for metastasis or suspected metastasis of axillary lymph nodes, among whom two patients did not develop axillary lymph nodes metastasis. Pathology of twenty-one cases was invasive ductal carcinoma with three cases of ductal carcinoma in situ and two cases of mucinous carcinoma. Twenty-five cases were luminal type breast cancer with ten cases of luminal A and fifteen cases of luminal B. Only one case was triple negative breast cancer. In staging, there were three cases in stage 0, eight cases in stage I, ten cases in stage II, and five cases in stage III.

Fifteen patients received adjuvant chemotherapy. Nine patients received eight cycles of chemotherapy containing anthracycline and taxane, and the other six patients received four cycles of chemotherapy containing taxane. Ten patients received adjuvant radiotherapy for lymph nodes metastasis. Twenty-five patients received adjuvant endocrine therapy, including tamoxifen for twenty-one patients and gonadotropin-releasing hormone agonist (GnRHa) combined with aromatase inhibitor (AI) for four patients. All cases were human epidermal growth factor receptor 2 (HER2) negative breast cancer. None of patients received anti-HER2 therapy. During the median follow-up period of 37 months, one patient died of previous lung cancer recurrence (he received lung cancer surgery 2 years before breast cancer surgery. Lung cancer and breast cancer were both primary cancer), and one patient developed lung metastases 2 years after breast surgery. No recurrence or distant metastasis occurred in the other twenty-four patients. The survival time of the death case after breast surgery was 26 months. Details were listed in Table 1.

Table 1

Characteristics of case series of male breast cancer

Characteristic	Number of patients	Percentages of the patients
Age
≥ 60	15	58%
< 60	11	42%
Type of BC surgery
Mastectomy + SLNB	12	46%
Mastectomy + SLNB + ALND	1	4%
Mastectomy + ALND	11	42%
Accessory mastectomy + ALND	1	4%
Accessory mastectomy + SLNB + ALND	1	4%
Histological type
DCIS	3	11%
IDC	21	81%
MC	2	8%
T stage
Tis	3	11%
T1	17	65%
T2	6	23%
T3	0
N stage
N0	13	50%
N1	8	31%
N2	2	8%
N3	3	11%
Stage
0	3	11%
I	8	31%
II	10	38%
III	5	19%
ER/PR status
ER and/or PR positive	25	96%
ER negative and PR negative	1	4%
HER2 status
Positive	0	0%
Negative	26	100%
Chemotherapy
None	11	42%
TC*4	6	23%
EC4-T4	9	35%
Radiotherapy
None	16	62%
Received	10	38%
Endocrine therapy
None	1	4%
TAM	21	81%
GnRHa + AI	4	15%
Events
None	24	92%
Recurrence	1*	4%
Death	1**	4%

BC breast cancer, SLNB sentinel lymph node biopsy, ALND axillary lymph node dissection, DCIS ductal carcinoma in situ, IDC invasive ductal carcinoma, MC mucinous carcinoma, ER estrogen-receptor, PR progesterone-receptor, HER2 human epidermal growth factor receptor 2, TC taxane and cyclophosphamide, EC epirubicin and cyclophosphamide, TAM tamoxifen, GnRHa gonadotropin-releasing hormone agonist, AI aromatase inhibitor

^*One patient got lung metastasis 2 years after initial breast surgery

^**One patient died of previous lung cancer 26 months after breast surgery

Discussion

The incidence of male breast cancer is low, accounting for less than 1% of all cases of breast cancer. However, the incidence of male breast cancer is increasing with growing rate of male gynecomastia in recent years [2]. Most male breast cancer occurs in elderly men [2, 4, 6]. Here, we describe the diagnosis and treatment of male breast cancer based on clinical guidelines and our case series.

The diagnosis of male breast cancer is similar to that of female breast cancer. Pathology is the gold standard [8]. Physical examination, ultrasound, mammography, and magnetic resonance help make clinic diagnosis. Physical examination included palpation of breast masses and axillary lymph nodes. The size, consistency, boundary, and mobility of tumor should be assessed. Male breast cancer is usually a hard mass with ill defined margins and poor mobility [9]. Ultrasound and mammography are routine preoperative examinations for breast diseases. Under breast ultrasound, male breast cancer is usually a mass with unclear boundaries, incomplete capsule, and abundant vascular supplication [10]. Mammography is difficult to carry out in male patients. Experienced mammography technicians are required to operate on account of a certain amount of breast tissue. Breast cancer in mammography is characterized by high density mass, unclear boundaries, and burrs [11]. For most patients, enhanced magnetic resonance is less available than ultrasound and mammography. It costs more and takes more time to receive enhanced magnetic resonance. In enhanced magnetic resonance, male breast cancer is characterized by irregular shape and enhanced signal of lesion [12]. Based on the above examination, we make the diagnosis of male breast cancer in clinic. Histopathological examination is required to make the final diagnosis.

Surgery

Surgery is the main treatment for early operable male breast cancer [13]. Mastectomy is the most common surgery for male patients with breast cancer. Sentinel lymph node biopsy can be applied for patients whose axillary lymph nodes are considered negative clinically. If the sentinel lymph nodes are negative, axillary lymph nodes dissection could be avoided. If the sentinel lymph nodes are positive, the surgeon may continue axillary lymph node dissection [14, 15]. Modified radical mastectomy (mastectomy + axillary lymph nodes dissection) is used for patients with suspected metastasis of axillary lymph nodes. Evidence shows that breast conserving surgery for male patients with breast cancer is feasible under the condition that the margin is negative and patients have the desire to receive breast conserving surgery [16, 17, 18]. However, in clinical practice, most of the male patients with breast cancer have limited breast tissue concentrated under nipple and areola, leading to breast mass located near the nipple. Those patients lose the chance of breast conserving surgery. Also, majority of male patients with breast cancer do not have a strong desire to undergo a breast conserving surgery in our experience. All patients in our case series received mastectomy or accessory mastectomy.

Chemotherapy

The application of chemotherapy in male patients with breast cancer is similar to that of female patients. The prognosis of male breast cancer is worse than that of female breast cancer. Male sex is a risk factor of prognosis [2, 13]. In our experience, chemotherapy is an important therapy for male patients with breast cancer. We should make a careful consideration before avoiding chemotherapy for male patients with breast cancer except for ductal carcinoma in situ or favorable histologic types such as pure tubular carcinoma and pure mucinous carcinoma. Between 1974 and 1988, a prospective study of adjuvant chemotherapy in male breast cancer was conducted by the American National Cancer Institute. Thirty-one male patients with breast cancer and lymph nodes metastasis were enrolled. The result showed that the 5-year, 10-year, and 20-year survival rates of patients undergoing adjuvant chemotherapy were 80%, 65%, and 42%, respectively, superior to historical control [19]. An observational cohort study showed that adjuvant chemotherapy for male patients with breast cancer could improve the prognosis [20]. Oncotype DX and other gene prognostic models could be applied to assess risk of distant recurrence and help clinician decide whether adjuvant chemotherapy is necessary for hormone receptor positive male breast cancer patients [21]. In our study, most patients (15 out of 21) with invasive ductal carcinoma received four to eight cycles of chemotherapy containing anthracycline or taxane. Most of them achieved good prognosis during the follow-up period.

Endocrine Therapy

In our retrospective study, 96% of male breast cancer is hormone receptor positive breast cancer. Tamoxifen is the gold standard of endocrine therapy for male patients with hormone receptor positive breast cancer [22, 23]. If tamoxifen is contraindicated, AI combined with gonadotropin-releasing hormone agonist could be a choice. AI monotherapy cannot be used in male patients with breast cancer. AI monotherapy plays an opposite role due to negative feedback regulation [24]. There is no evidence showing that GnRHa plus AI is superior to tamoxifen in male breast cancer [13]. As a selective estrogen receptor degrader, fulvestrant has been proved to be effective in the treatment of male breast cancer [25]. However, the guideline does not recommend use of fulvestrant as adjuvant therapy for male patients with breast cancer [26]. Cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors also have not been recommended to be used in adjuvant therapy for male patients with breast cancer [26]. In our study, most male patients with breast cancer received tamoxifen monotherapy and achieved good results.

Radiotherapy

The adjuvant radiotherapy applied to male breast cancer is similar to that used for female patients with breast cancer. Adjuvant radiotherapy is recommended for patients with axillary lymph node metastasis or undergoing breast conserving surgery. Postoperative radiotherapy is also recommended for patients with tumors larger than 5 cm [13, 26]. Those patients need to receive chest wall and related lymph node drainage area radiotherapy. An observational study showed that male patients with breast cancer and lymph nodes metastasis benefited from radiotherapy [27]. In our study, almost all the patients with lymph nodes metastasis received radiotherapy except for 3 patients with poor tolerance (2 patients were over 80 years old and 1 patient had psychiatric illness).

Targeted therapy

For HER2 positive male patients, adjuvant targeted therapy combining trastuzumab is required. Similar to female breast cancer, clinician recommends trastuzumab for lymph node negative HER2 positive patients and trastuzumab plus pertuzumab for lymph nodes positive HER2 positive patients. Male patients with other high risk of recurrence (such as T > 5 cm, age < 35) could be recommended trastuzumab plus pertuzumab [3, 5, 13, 14]. However, the rate of HER2 overexpression in male breast cancer is low. In our study, none of the 26 male patients got HER2 positive breast cancer, and none of them received anti-HER2 therapy.

We have searched the PubMed for case series of male breast cancer published in the last decade. Twenty-four retrospective studies are found [3, 28-50]. Some data was collected from last four decades with missing or not available information. Male breast cancer is rare. Most case series from single center contained less than twenty patients. Data of large-scale studies come from multicenter or national database. Like our study, most studies showed male patients with breast cancer have ER or PR positive and HER2 negative disease. One study showed 52.4% HER2 positive disease in 69 patients [31]. It is interesting for such high percentage of HER2 positive disease. More attention should be paid to find the reasons. Ki-67 value was reported in five studies with different cut-off values (20% in three studies and 14% in two studies) [31, 33, 40, 42, 45]. We select 20% as Ki-67 cut-off value to build Table 2. Our study showed 17/26 patients had lower Ki-67 value (≤ 20%), while two of five studies showed more patients had higher Ki-67 values [33, 42]. It showed male patients with breast cancer did not mean high Ki-67 values. Details are listed in Table 2.

Table 2

Case series of male breast cancer published in the last decade

First author	N	ER		PR		HER2		Ki-67
First author	N	ER+	ER-	PR+	PR-	HER2+	HER2-	＞20%	≤20%
Aggarwal A (2021) [28]	1528	59%	2%	52.8%	7.9%	NA	NA	NA	NA
Lomma C (2021) [29]	585	ER+ and/or PR+ 94%				7%	85%	NA	NA
Lomma C (2021) [29]	585	ER- and PR- 2%				7%	85%	NA	NA
Johnson, A.E (2021) [30]	100	93%	NA	90%	NA	5%	91%	NA	NA
Pellini F (2020) [31]	69	96.6%	3.4%	94.6%	5.4%	52.4%	47.6%	37.3%	62.7%
Yetkin G (2019) [32]	15	93.3%	6.7%	86.7%	13.3%	13.3%	86.7%	NA	NA
M. K. Chhabra (2019) [3]	106	81%	NA	74%	NA	25%	75%	NA	NA
Oana Cristina V (2018) [33]	6	100%	0%	83.3%	16.7%	0%	100%	83.3%	16.7%
Wan BA (2018) [34]	161	78.3%	1.9%	70.2%	9.3%	9.9%	54.7%	NA	NA
Weir J (2018) [35]	23305	ER+ and/or PR+ 92.2%				11.6%	NA	NA	NA
McKinley N (2017) [36]	22	77.3%	0%	40.9%	0%	0%	36.4%	NA	NA
Rayne S (2017) [37]	23	96%	4%	87%	13%	13%	74%	NA	NA
Vermeulen MA (2017) [38]	1483	ER+ and/or PR+ 93%				7.3%	86.6%	NA	NA
Vermeulen MA (2017) [38]	1483	ER- and PR- 1%				7.3%	86.6%	NA	NA
Madden NA (2016) [39]	1337	68%	5%	59%	13%	NA	NA	NA	NA
Masci G (2015) [40]	91	96.7%	3.3%	92.3%	7.7%	14.2%	79.2%	35.2%	57.1%
Bradley KL (2014) [41]	158	96%	3%	91%	8%	6%	62%	NA	NA
Iorfida M (2014) [42]	99	97%	3%	88%	12%	8%	90%	NA	NA
Rushton M (2014) [43]	72	81.4%	NA	72.2%	5.6%	5.6%	34.7%	NA	NA
Fogh S (2013) [44]	42	100%	0%	100%	0%	NA	NA	NA	NA
Nilsson C (2013) [45]	197	92.9%	4.6%	79.7%	19.3%	10.6%	83.2%	NA	NA
Yu XF (2013) [46]	68	ER+ and/or PR+ 85.3%				35.3%	64.7%	NA	NA
Yu XF (2013) [46]	68	ER- and PR- 14.7%				35.3%	64.7%	NA	NA
Arslan UY (2012) [47]	118	82.9%	17.1%	75.8%	24.2%	23.4%	76.7%	NA	NA
Dabakuyo TS (2012) [48]	75	72%	12%	65.3%	14.6%	NA	NA	NA	NA
Müller AC (2012) [ 49]	40	65%	17.5%	60%	17.5%	15%	20%	NA	NA
Yu E (2012) [50]	81	82.7%	1.3%	70.7%	10.7%	NA	NA	NA	NA

ER estrogen-receptor, PR progesterone-receptor, HER2 human epidermal growth factor receptor 2, NA not available

Conclusion

The incidence of male breast cancer is low. In this study, we present twenty-six cases of male patients with operable breast cancer in our department. All of them received surgery and adjuvant treatment. During the median follow-up period of 37 months, most patients do not have recurrence or distant metastasis disease. Early diagnosis and combined therapy benefit male patients with breast cancer. Surgery together with adjuvant treatment can bring a good prognosis.

Declarations

The studies involving human participants were reviewed and approved by the ethics committee of Hwa Mei Hospital, University of Chinese Academy of Sciences. The patients/participants provided their written informed consent to participate in this study.

Conflict of Interests

The authors declare no competing interests.

Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Unsere Produktempfehlungen

Die Chirurgie

Print-Titel

Das Abo mit mehr Tiefe

Mit der Zeitschrift Die Chirurgie erhalten Sie zusätzlich Online-Zugriff auf weitere 43 chirurgische Fachzeitschriften, CME-Fortbildungen, Webinare, Vorbereitungskursen zur Facharztprüfung und die digitale Enzyklopädie e.Medpedia.

Jetzt informieren

e.Med Interdisziplinär

Kombi-Abonnement

Jetzt e.Med zum Sonderpreis bestellen!

Für Ihren Erfolg in Klinik und Praxis - Die beste Hilfe in Ihrem Arbeitsalltag

Mit e.Med Interdisziplinär erhalten Sie Zugang zu allen CME-Fortbildungen und Fachzeitschriften auf SpringerMedizin.de.

Jetzt bestellen und 100 € sparen!

Jetzt testen ¹

Globocan. Breast cancer fact sheet (2020) Available from: http://gco.iarc.fr/today/data/factsheets/populations/900-world-fact-sheets.pdf. Accessed 1 Jan 2022

Abdelwahab Yousef AJ (2017) Male breast cancer: epidemiology and risk factors. Semin Oncol 44(4):267–272. https://doi.org/10.1053/j.seminoncol.2017.11.002CrossRefPubMed

Chhabra MK, Chintamani MK et al (2019) Male breast cancer-an Indian multicenter series of 106 cases. Indian J Surg 83(Suppl 2):333–340

Liu N, Johnson KJ, Ma CX (2018) Male breast cancer: an updated surveillance, epidemiology, and end results data analysis. Clin Breast Cancer 18(5):e997–e1002. https://doi.org/10.1016/j.clbc.2018.06.013CrossRefPubMed

Mattson J, Vehmanen L (2016) Miehen rintasyöpä [Male breast cancer]. Duodecim 132(7):627–31. Finnish

Leon-Ferre RA, Giridhar KV, Hieken TJ, Mutter RW, Couch FJ, Jimenez RE, Hawse JR, Boughey JC, Ruddy KJ (2018) A contemporary review of male breast cancer: current evidence and unanswered questions. Cancer Metastasis Rev 37(4):599–614. https://doi.org/10.1007/s10555-018-9761-xCrossRefPubMed

Gucalp A, Traina TA, Eisner JR, Parker JS, Selitsky SR, Park BH, Elias AD, Baskin-Bey ES, Cardoso F (2019) Male breast cancer: a disease distinct from female breast cancer. Breast Cancer Res Treat 173(1):37–48. https://doi.org/10.1007/s10549-018-4921-9CrossRefPubMed

Nofal MN, Yousef AJ (2019) The diagnosis of male breast cancer. Neth J Med 77(10):356–359PubMed

Goss PE, Reid C, Pintilie M, Lim R, Miller N (1999) Male breast carcinoma: a review of 229 patients who presented to the Princess Margaret Hospital during 40 years: 1955–1996. Cancer 85(3):629–639. https://doi.org/10.1002/(sici)1097-0142(19990201)85:3%3c629::aid-cncr13%3e3.0.co;2-vCrossRefPubMed

10.

Mainiero MB, Lourenco AP, Barke LD, Argus AD, Bailey L, Carkaci S, D’Orsi C, Green ED, Holley SO, Jokich PM, Lee SJ, Mahoney MC, Moy L, Slanetz PJ, Trikha S, Yepes MM, Newell MS (2015) ACR appropriateness criteria evaluation of the symptomatic male breast. J Am Coll Radiol 12(7):678–682. https://doi.org/10.1016/j.jacr.2015.03.024CrossRefPubMed

11.

Doyle S, Steel J, Porter G (2011) Imaging male breast cancer. Clin Radiol 66(11):1079–1085. https://doi.org/10.1016/j.crad.2011.05.004CrossRefPubMed

12.

Shin K, Martaindale S, Whitman GJ (2019) Male breast magnetic resonance imaging: when is it helpful? Our experience over the last decade. Curr Probl Diagn Radiol 48(3):196–203. https://doi.org/10.1067/j.cpradiol.2018.01.002CrossRefPubMed

13.

Giordano SH (2018) Breast cancer in men. N Engl J Med 378(24):2311–2320. https://doi.org/10.1056/NEJMra1707939CrossRefPubMed

14.

Cardoso F, Bartlett JMS, Slaets L, van Deurzen CHM, van Leeuwen-Stok E, Porter P, Linderholm B, Hedenfalk I, Schröder C, Martens J, Bayani J, van Asperen C, Murray M, Hudis C, Middleton L, Vermeij J, Punie K, Fraser J, Nowaczyk M, Rubio IT, Aebi S, Kelly C, Ruddy KJ, Winer E, Nilsson C, Lago LD, Korde L, Benstead K, Bogler O, Goulioti T, Peric A, Litière S, Aalders KC, Poncet C, Tryfonidis K, Giordano SH (2018) Characterization of male breast cancer: results of the EORTC 10085/TBCRC/BIG/NABCG International Male Breast Cancer Program. Ann Oncol 29(2):405–417. https://doi.org/10.1093/annonc/mdx651CrossRefPubMed

15.

Fentiman IS (2018) Surgical options for male breast cancer. Breast Cancer Res Treat 172(3):539–544. https://doi.org/10.1007/s10549-018-4952-2CrossRefPubMedPubMedCentral

16.

Cloyd JM, Hernandez-Boussard T, Wapnir IL (2013) Outcomes of partial mastectomy in male breast cancer patients: analysis of SEER, 1983–2009. Ann Surg Oncol 20(5):1545–1550. https://doi.org/10.1245/s10434-013-2918-5CrossRefPubMed

17.

Zaenger D, Rabatic BM, Dasher B, Mourad WF (2016) Is breast conserving therapy a safe modality for early-stage male breast cancer? Clin Breast Cancer 16(2):101–104. https://doi.org/10.1016/j.clbc.2015.11.005CrossRefPubMed

18.

Bateni SB, Davidson AJ, Arora M, Daly ME, Stewart SL, Bold RJ, Canter RJ, Sauder CAM (2019) Is breast-conserving therapy appropriate for male breast cancer patients? A National Cancer Database analysis. Ann Surg Oncol 26(7):2144–2153. https://doi.org/10.1245/s10434-019-07159-4CrossRefPubMedPubMedCentral

19.

Walshe JM, Berman AW, Vatas U, Steinberg SM, Anderson WF, Lippman ME, Swain SM (2007) A prospective study of adjuvant CMF in males with node positive breast cancer: 20-year follow-up. Breast Cancer Res Treat 103(2):177–183. https://doi.org/10.1007/s10549-006-9363-0CrossRefPubMed

20.

Patel HZ 2nd, Buzdar AU, Hortobagyi GN (1989) Role of adjuvant chemotherapy in male breast cancer. Cancer 64(8):1583–1585. https://doi.org/10.1002/1097-0142(19891015)64:8%3c1583::aid-cncr2820640804%3e3.0.co;2-qCrossRefPubMed

21.

Grenader T, Yerushalmi R, Tokar M, Fried G, Kaufman B, Peretz T, Geffen DB (2014) The 21-gene recurrence score assay (Oncotype DX™) in estrogen receptor-positive male breast cancer: experience in an Israeli cohort. Oncology 87(1):1–6. https://doi.org/10.1159/000360793CrossRefPubMed

22.

Mauras N, O’Brien KO, Klein KO, Hayes V (2000) Estrogen suppression in males: metabolic effects. J Clin Endocrinol Metab 85(7):2370–2377. https://doi.org/10.1210/jcem.85.7.6676CrossRefPubMed

23.

Eggemann H, Ignatov A, Smith BJ, Altmann U, von Minckwitz G, Röhl FW, Jahn M, Costa SD (2013) Adjuvant therapy with tamoxifen compared to aromatase inhibitors for 257 male breast cancer patients. Breast Cancer Res Treat 137(2):465–470. https://doi.org/10.1007/s10549-012-2355-3CrossRefPubMed

24.

Hayes FJ, Seminara SB, Decruz S, Boepple PA, Crowley WF Jr (2000) Aromatase inhibition in the human male reveals a hypothalamic site of estrogen feedback. J Clin Endocrinol Metab 85(9):3027–3035. https://doi.org/10.1210/jcem.85.9.6795CrossRefPubMed

25.

Zagouri F, Sergentanis TN, Chrysikos D, Dimopoulos MA, Psaltopoulou T (2015) Fulvestrant and male breast cancer: a pooled analysis. Breast Cancer Res Treat 149(1):269–275. https://doi.org/10.1007/s10549-014-3240-zCrossRefPubMed

26.

National Comprehensive Cancer Network (2020) Available from: https://www.nccn.org/professionals/physician_gls/default.aspx#breast. Accessed 29 Dec 2020

27.

Abrams MJ, Koffer PP, Wazer DE, Hepel JT (2017) Postmastectomy radiation therapy is associated with improved survival in node-positive male breast cancer: a population analysis. Int J Radiat Oncol Biol Phys 98(2):384–391. https://doi.org/10.1016/j.ijrobp.2017.02.007CrossRefPubMed

28.

Aggarwal A, Adepoju B, Yacur M, Maron D, Sharma MC (2021) Gender disparity in breast cancer: a veteran population-based comparison. Clin Breast Cancer 21(4):e471–e478. https://doi.org/10.1016/j.clbc.2021.01.013CrossRefPubMed

29.

Lomma C, Chan A, Chih H, Reid C, Peter W (2021) Male breast cancer in Australia. Asia Pac J Clin Oncol 17(2):e57–e62. https://doi.org/10.1111/ajco.13299CrossRefPubMed

30.

Johnson AE, Coopey SB, Spring LM et al (2021) Management and outcomes of men diagnosed with primary breast cancer. Breast Cancer Res Treat 188:561–569. https://doi.org/10.1007/s10549-021-06174-yCrossRefPubMed

31.

Pellini F, Granuzzo E, Urbani S, Mirandola S, Caldana M, Lombardi D, Fiorio E, Mandarà M, Pollini GP (2020) Male breast cancer: surgical and genetic features and a multidisciplinary management strategy. Breast Care (Basel) 15(1):14–20. https://doi.org/10.1159/000501711CrossRefPubMed

32.

Yetkin G, Celayir MF, Tanik C, Citgez B, Uludag M, Mihmanli M (2019) Male breast cancer: a 10 year retrospective case series in a tertiary care hospital. J Pak Med Assoc 69(8):1209–1212PubMed

33.

Oana Cristina V, Monica Mihaela C, Daniel I, Maria S, Adrian Vasile D, Oana Mari P, Dan-Corneliu J, Adriana Elena N (2018) Histology of male breast lesions. Series of cases and literature review. Maedica (Bucur) 13(3):196–201. https://doi.org/10.26574/maedica.2018.13.3.196CrossRefPubMed

34.

Wan BA, Ganesh V, Zhang L, Sousa P, Drost L, Lorentz J, Vesprini D, Lee J, Rakovitch E, Lu FI, Eisen A, Yee C, Lam H, Chow E (2018) Treatment outcomes in male breast cancer: a retrospective analysis of 161 patients. Clin Oncol (R Coll Radiol) 30(6):354–365. https://doi.org/10.1016/j.clon.2018.02.026CrossRefPubMed

35.

Weir J, Zhao YD, Herman T, Algan Ö (2018) Clinicopathologic features and radiation therapy utilization in patients with male breast cancer: a National Cancer Database study. Breast Cancer (Auckl) 20(12):1178223418770687. https://doi.org/10.1177/1178223418770687CrossRef

36.

McKinley N, McCain S, Kirk S (2017) Long term follow up of male breast cancer. Ulster Med J 86(3):177–180PubMedPubMedCentral

37.

Rayne S, Schnippel K, Thomson J, Reid J, Benn C (2017) Male breast cancer has limited effect on survivor’s perceptions of their own masculinity. Am J Mens Health 11(2):246–252. https://doi.org/10.1177/1557988316631512CrossRefPubMed

38.

Vermeulen MA, Slaets L, Cardoso F, Giordano SH, Tryfonidis K, van Diest PJ, Dijkstra NH, Schröder CP, van Asperen CJ, Linderholm B, Benstead K, Foekens R, Martens JWM, Bartlett JMS, van Deurzen CHM (2017) Pathological characterisation of male breast cancer: results of the EORTC 10085/TBCRC/BIG/NABCG International Male Breast Cancer Program. Eur J Cancer 82:219–227. https://doi.org/10.1016/j.ejca.2017.01.034CrossRefPubMed

39.

Madden NA, Macdonald OK, Call JA, Schomas DA, Lee CM, Patel S (2016) Radiotherapy and male breast cancer: a population-based registry analysis. Am J Clin Oncol 39(5):458–462. https://doi.org/10.1097/COC.0000000000000078CrossRefPubMed

40.

Masci G, Caruso M, Caruso F, Salvini P, Carnaghi C, Giordano L, Miserocchi V, Losurdo A, Zuradelli M, Torrisi R, Di Tommaso L, Tinterri C, Testori A, Garcia-Etienne CA, Gatzemeier W, Santoro A (2015) Clinicopathological and immunohistochemical characteristics in male breast cancer: a retrospective case series. Oncologist 20(6):586–592. https://doi.org/10.1634/theoncologist.2014-0243CrossRefPubMedPubMedCentral

41.

Bradley KL, Tyldesley S, Speers CH, Woods R, Villa D (2014) Contemporary systemic therapy for male breast cancer. Clin Breast Cancer 14(1):31–39. https://doi.org/10.1016/j.clbc.2013.09.001CrossRefPubMed

42.

Iorfida M, Bagnardi V, Rotmensz N, Munzone E, Bonanni B, Viale G, Pruneri G, Mazza M, Cardillo A, Veronesi P, Luini A, Galimberti V, Goldhirsch A, Colleoni M (2014) Outcome of male breast cancer: a matched single-institution series. Clin Breast Cancer 14(5):371–377. https://doi.org/10.1016/j.clbc.2014.02.008CrossRefPubMed

43.

Rushton M, Kwong A, Visram H, Graham N, Petrcich W, Dent S (2014) Treatment outcomes for male breast cancer: a single-centre retrospective case-control study. Curr Oncol 21(3):e400–e407. https://doi.org/10.3747/co.21.1730CrossRefPubMedPubMedCentral

44.

Fogh S, Kachnic LA, Goldberg SI, Taghian AG, Powell SN, Hirsch AE (2013) Localized therapy for male breast cancer: functional advantages with comparable outcomes using breast conservation. Clin Breast Cancer 13(5):344–349. https://doi.org/10.1016/j.clbc.2013.05.004CrossRefPubMed

45.

Nilsson C, Johansson I, Ahlin C, Thorstenson S, Amini RM, Holmqvist M, Bergkvist L, Hedenfalk I, Fjällskog ML (2013) Molecular subtyping of male breast cancer using alternative definitions and its prognostic impact. Acta Oncol 52(1):102–109. https://doi.org/10.3109/0284186X.2012.711952CrossRefPubMed

46.

Yu XF, Feng WL, Miao LL, Chen B, Yang HJ (2013) The prognostic significance of molecular subtype for male breast cancer: a 10-year retrospective study. Breast 22(5):824–827. https://doi.org/10.1016/j.breast.2013.02.005CrossRefPubMed

47.

Arslan UY, Oksüzoğlu B, Ozdemir N, Aksoy S, Alkış N, Gök A, Kaplan MA, Gümüş M, Berk V, Uncu D, Baykara M, Colak D, Uyetürk U, Türker I, Işıkdoğan A (2012) Outcome of non-metastatic male breast cancer: 118 patients. Med Oncol 29(2):554–560. https://doi.org/10.1007/s12032-011-9978-9CrossRefPubMed

48.

Dabakuyo TS, Dialla O, Gentil J, Poillot ML, Roignot P, Cuisenier J, Arveux P (2012) Breast cancer in men in Cote d’Or (France): epidemiological characteristics, treatments and prognostic factors. Eur J Cancer Care (Engl) 21(6):809–816. https://doi.org/10.1111/j.1365-2354.2012.01365.xCrossRefPubMed

49.

Müller AC, Gani C, Rehm HM, Eckert F, Bamberg M, Hehr T, Weinmann M (2012) Are there biologic differences between male and female breast cancer explaining inferior outcome of men despite equal stage and treatment?! Strahlenther Onkol 188(9):782–787. https://doi.org/10.1007/s00066-012-0118-zCrossRefPubMed

50.

Yu E, Suzuki H, Younus J, Elfiki T, Stitt L, Yau G, Vujovic O, Perera F, Lock M, Tai P (2012) The impact of post-mastectomy radiation therapy on male breast cancer patients—a case series. Int J Radiat Oncol Biol Phys 82(2):696–700. https://doi.org/10.1016/j.ijrobp.2011.01.010CrossRefPubMed

Titel: Case Series Analysis of Male Breast Cancer
verfasst von: Chao Li
Xujun Li
Publikationsdatum: 06.09.2022
Verlag: Springer India
Erschienen in: Indian Journal of Surgery / Ausgabe 4/2023
Print ISSN: 0972-2068
Elektronische ISSN: 0973-9793
DOI: https://doi.org/10.1007/s12262-022-03559-1

Neu im Fachgebiet Chirurgie

Häusliche Gewalt in der orthopädischen Notaufnahme oft nicht erkannt

28.05.2024 Häusliche Gewalt Nachrichten

In der Notaufnahme wird die Chance, Opfer von häuslicher Gewalt zu identifizieren, von Orthopäden und Orthopädinnen offenbar zu wenig genutzt. Darauf deuten die Ergebnisse einer Fragebogenstudie an der Sahlgrenska-Universität in Schweden hin.

Fehlerkultur in der Medizin – Offenheit zählt!

28.05.2024 Fehlerkultur Podcast

Darüber reden und aus Fehlern lernen, sollte das Motto in der Medizin lauten. Und zwar nicht nur im Sinne der Patientensicherheit. Eine negative Fehlerkultur kann auch die Behandelnden ernsthaft krank machen, warnt Prof. Dr. Reinhard Strametz. Ein Plädoyer und ein Leitfaden für den offenen Umgang mit kritischen Ereignissen in Medizin und Pflege.

Mehr Frauen im OP – weniger postoperative Komplikationen

21.05.2024 Allgemeine Chirurgie Nachrichten

Ein Frauenanteil von mindestens einem Drittel im ärztlichen Op.-Team war in einer großen retrospektiven Studie aus Kanada mit einer signifikanten Reduktion der postoperativen Morbidität assoziiert.

TAVI versus Klappenchirurgie: Neue Vergleichsstudie sorgt für Erstaunen

21.05.2024 TAVI Nachrichten

Bei schwerer Aortenstenose und obstruktiver KHK empfehlen die Leitlinien derzeit eine chirurgische Kombi-Behandlung aus Klappenersatz plus Bypass-OP. Diese Empfehlung wird allerdings jetzt durch eine aktuelle Studie infrage gestellt – mit überraschender Deutlichkeit.

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Aktuelle BDC Leitlinien-Webinare

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

Karpaltunnelsyndrom BDC Leitlinien Webinare

CME: 2 Punkte

Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis

S2e-Leitlinie „Distale Radiusfraktur“

Radiusfraktur BDC Leitlinien Webinare

CME: 2 Punkte

Das Webinar beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske

Dr. med. Benjamin Meyknecht

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

Appendizitis BDC Leitlinien Webinare

CME: 2 Punkte

Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Case Series Analysis of Male Breast Cancer

Abstract

Publisher’s Note

Introduction

Patients and Methods

Result